Cadaver fat, boob jobs, and a pickup truck: Company accused of scheming to smuggle hot new filler to NY doctors

In a shocking turn of events, allegations have surfaced against Tiger Medical Holdings regarding the illegal distribution of alloClae, a new injectable filler made from processed cadaver fat. On a chilly December day, nine large boxes labeled as perishable were spotted in a New Jersey driveway, sparking concerns about the product's journey to high-end cosmetic practices in New York City. New York State health officials recently filed court documents accusing Tiger Medical Holdings of smuggling the potentially lucrative filler into the state without the required permissions. The company maintains that only the FDA has the jurisdiction to regulate alloClae, arguing that it is not subject to premarket approval. However, New York's stringent laws concerning human tissue distribution are said to have been violated. With evidence obtained from FedEx records, officials claim that Tiger orchestrated a scheme to transport over $1 million worth of alloClae into New York. The product has gained immense popularity among busy professionals seeking quick cosmetic enhancements, allowing patients to undergo procedures during their lunch breaks. Despite the ongoing investigation, reports indicate that demand for alloClae remains high, with many doctors continuing to use it. Tiger co-CEO Oliver Burckhardt noted that around 60 physicians have reached out to express concern or inquire about purchasing more of the filler amidst the controversy. The company has refuted the allegations of smuggling, labeling the state's evidence as unreliable and self-serving. They emphasized that they had been in ongoing communication with the health department, asserting that they submitted safety testing data as recently as January. Marketed as a revolutionary product, alloClae quickly captured the attention of plastic surgeons in New York City. The filler can be injected at costs ranging from under $10,000 for small quantities to upwards of $100,000 per procedure, appealing to clients who prioritize convenience and minimal downtime. Behind the scenes, the controversy escalated as state inspectors discovered that shipments of alloClae were being routed through New Jersey and Connecticut to bypass regulatory scrutiny. Internal communications revealed that Tiger's representatives reassured surgeons about the product's legality, even after warnings from the state's health department. As the investigation unfolds, some physicians have chosen to halt their use of alloClae, while others continue to promote it despite the looming legal challenges. The outcome of this case could significantly impact the availability of this high-demand cosmetic filler in New York's competitive market.